ADAMTS13 and thrombotic thrombocytopenic purpura: Among them, 420 were considered as having a TTP with an acquired/autoimmune severe ADAMTS13 deficiency fulfilling all inclusion criteria of the study; all were followed during at least 30 days after treatment initiation.